New member of Elekta’s Nomination Committee
Anna Ohlsson-Leijon, representing SEB funds, has been appointed to Elekta’s Nomination Committee. She replaces Tove Bångstad who has left her position at SEB. Anna Ohlsson-Leijon is an independent representative of the Board of Fondbolaget SEB Investment Management AB since three years.
The Nomination Committee that will prepare matters prior to the Annual General Meeting 2011 thereby consists of Åsa Nisell, Swedbank Robur funds, Anna Ohlsson-Leijon, SEB Funds, Ole E. Dahl, Orkla ASA, Laurent Leksell, representing his private and companies’ holdings, and Akbar Seddigh, Chairman of the Board.
For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, e-mail: firstname.lastname@example.org
Elekta AB (publ) discloses the information in this press release according to the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. The information was provided for public release on 31 January 2011 at 15.00 CET.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that give confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in more than 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs about 2,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.